APEPTICO is developing a portfolio of peptide-based products based on its PEPBASE™ discovery technology.

APEPTICO’s investigational compound solnatide (INN, laboratory code AP301) is a synthetically manufactured peptide, and was originally designed for the therapeutic treatment of patients with Pulmonary Permeability Oedema and various forms of life-threatening conditions, such as Acute Lung Dysfunction, ARDS, Lung Transplantation.

Orally inhaled solnatide has completed a first-in-man (FIM) Phase I clinical study, and has delivered clinical proof-of-concept in various randomised, placebo-controlled, double-blinded Phase II clinical studies in patients suffering from pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and other causes of life-threatening pulmonary dysfunction.

Solnatide has been assessed for safety in a phase IIB clinical study for the treatment of life-threatening pulmonary permeability oedema, and has been used for the treatment of severe ill COVID-19 patients following infection with the new corona virus (SARS-CoV-2).